1	Transcatheter Aortic Valve Replacement Use in Young Patients Before and After Low-Risk		
2	Indication Approval		
3			
4	Authors: Christina Waldron BS ¹ , Luigi Pirelli MD ² , Isaac George MD ² , Hiroo Takayama MD		
5	PhD ² , Arnar Geirsson MD ² , Roland Assi MD MMS ¹ , Makoto Mori MD PhD ³		
6			
7	¹ Division of Cardiac Surgery, Yale University School of Medicine, New Haven, CT		
8	² Division of Cardiac, Thoracic and Vascular Surgery, Columbia University, NY, New York		
9	³ Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT		
10			
11	IRB protocol number: 2000028791, approved on 9/2/23		
12			
13	Disclosures:		
14	Dr. Geirsson receives a consulting fee from Medtronic and Edwards Lifesciences.		
15	All other authors have nothing to disclose.		
16			
17	Corresponding author:	Makoto Mori, MD PhD	
18 19 20 21 22 23 24 25 26		Division of Cardiac Surgery Yale School of Medicine BB204, 330 Cedar Street P.O. Box 208039, 06510 New Haven, CT Business phone: 203-785-6214 Fax: 203-785-3346 Email: <u>makoto.mori@yale.edu</u>	
_			

27 Word Count (1077/1200)

28 Abstract

29 Transcatheter aortic valve replacement (TAVR) use in young patients has recently increased 30 following FDA approval for use in low-risk patients. How TAVR use among young patients may 31 have accelerated in the interval between the FDA approval and the guideline publication remain 32 unknown. We sought to characterize the national trends in a ortic valve replacement (AVR) 33 among young patients before and after the low-risk indication approval. Using the National 34 Inpatient Sample data, we conducted a cross-sectional study of patients younger than 65 years of 35 age who underwent TAVR, SAVR, or Ross operations between January 1, 2016, and February 36 29, 2020. We compared in-hospital mortality before and after the low-risk indication approval to 37 infer whether the expansion occurred among lower-risk strata within the TAVR group in relation 38 to SAVR. We identified 106,340 AVRs, including 13,095 TAVR (12.3%), 63,620 bioprosthetic 39 SAVR (59.8%), 28,370 mechanical SAVR (26.7%), and 1,255 Ross (1.2%). The mean age was 40 54 (10.9), including 32,775 (30.8%) women. Before and after the low-risk approval, the TAVR 41 share increased at 0.25 (0.03%) and 0.60 (0.09%) per month, respectively (interaction term p-42 value <0.001). Expansion of TAVR use among young patients around the time of FDA approval 43 in low surgical risk patients serves as a case study to highlight the potential importance of 44 specifying the indicated age group in future FDA approvals of transcatheter valve intervention 45 devices.

46

47 Introduction

48 Transcatheter aortic valve replacement (TAVR) use in young patients has recently
49 increased¹. The U.S. Food and Drug Administration (FDA) approval of balloon-expanded and
50 self-expandable TAVR devices for low-risk patients did not specify the indicated age group,

51	although the participants in both pivotal trials, PARTNER 3 and Evolut low-risk trials, were old		
52	at a mean age of 73 ^{2,1} . The high-risk nature of TAVR explant and unknown long-term valve		
53	durability are important considerations related to TAVR use among young patients with expected		
54	longevity ³ . While the current U.S. guideline recommends surgical aortic valve replacement		
55	(SAVR) in low-risk patients younger than 65 ⁴ , the first guideline specifying such age threshold		
56	was published in 2020, 2 years after the first FDA approval of TAVR for low-risk patients. How		
57	TAVR use among young patients may have accelerated in the interval between the FDA approval		
58	and the guideline publication remain unknown.		
59	Numerous trials are underway to evaluate transcatheter valve repair and replacement in		
60	non-aortic positions. With expected data lag and guideline publication lag accounting for the		
61	device durability and long-term outcomes, examining the rapidity of TAVR use expansion in		
62	young patients around the time of low-risk TAVR approval may serve as a case study to inform		
63	the nuances of future FDA approval of devices currently undergoing trials ⁵ .		
64	To understand how the low-risk indication approval may have accelerated TAVR		
65	utilization nationally in this age group, we characterized the national trends in aortic valve		
66	replacement (AVR) among young patients before and after the low-risk indication approval.		
67			
68	Methods		
69	Using the National Inpatient Sample (NIS) data, a 20% stratified sample of all inpatient		
70	discharges from US non-federal hospitals, we conducted a cross-sectional study of patients		
71	younger than 65 years of age who underwent TAVR, SAVR, or Ross operations between January		
72	1, 2016, and February 29, 2020 (the latest available year, up to the COVID-19 stay-at home		
73	order). Operations and aortic valve pathology were defined using the International Classification		

of Diseases, 10th revision (ICD-10) (Supplemental Table). Patients with endocarditis were 74 75 excluded. Difference-in-difference analysis estimated the association between the low-risk 76 indication approval on August 16, 2018 (cutoff on September 1, 2018) and the change in the 77 monthly percent TAVR share among all AVRs as a continuous variable (Supplemental Methods). 78 We compared in-hospital mortality before and after the low-risk indication approval to infer 79 whether the expansion occurred among lower-risk strata within the TAVR group in relation to 80 SAVR. 81 We used the 'survey' R package, applied the hospital discharge weight variable in the 82 NIS dataset to estimate the total national volume of index operations, and performed the chi-83 squared test, accounting for the sampled nature of the dataset. Difference-in-difference model 84 was specified with the outcome being the monthly percent of TAVR share among all AVRs, with 85 the covariates of the month as a nominal variable and a pre/post indicator of before and after 86 September 1, 2018. An interaction term was added as the product of the month and pre/post 87 indicator variable. 88 Analyses were performed in R version 4.2.2 (R Foundation). All P values were 2-sided, 89 with <0.05 denoting statistical significance. This study was approved by the Yale Institutional 90 Review Board. Informed consent was waived because the data were deidentified. 91 92 **Results** 93 We identified 106,340 AVRs, including 13,095 TAVR (12.3%), 63,620 bioprosthetic 94 SAVR (59.8%), 28,370 mechanical SAVR (26.7%), and 1,255 Ross (1.2%). The mean age was 95 54 ± 10.9 , including 32,775 (30.8%) women. The proportion of TAVR increased from 6.9% in

96	2016 to 22.4% in 2020. The shares of mechanical SAVR remained stable from 29.8% to 26%,
97	while bioprosthetic SAVR decreased from 62.2% to 50.9%.
98	Before and after the low-risk approval, the TAVR share increased at $0.25\pm0.03\%$ and
99	$0.60\pm0.09\%$ per month, respectively (interaction term <i>p</i> -value <0.001, Figure 1A). Among
100	patients undergoing TAVR, in-hospital mortality was 2.4% before and 1.1% after the approval
101	(p=0.015, Figure 1B). Among patients undergoing bioprosthetic SAVR, in-hospital mortality
102	was 2.5% before and 2% after ($p=0.1$), and for mechanical SAVR, in-hospital mortality was 3%
103	before and 3.5% after the approval ($p=0.28$). In-hospital mortality for patients undergoing the
104	Ross procedure was 1.9% before and 1.1% after approval ($p=0.67$).
105	Among patients younger than 50, TAVR share increased from 3.1% in 2016 to 6.7% in
106	2020. SAVR was increasingly performed for congenital pathology, including bicuspid valve
107	(18% of SAVR in 2016 to 29% in 2020), while the pathology composition remained stable for
108	TAVR.
109	
110	Discussion
111	We demonstrated that TAVR use in patients younger than 65 was increasing prior to the

We demonstrated that TAVR use in patients younger than 65 was increasing prior to the FDA approval for low-risk indication, and accelerated after the FDA approval, more than doubling the rate of monthly increase. The share of TAVR among all AVRs in this age group tripled between 2016 and 2020 preceding the publication of the first guideline specifying age threshold for low-risk TAVR. Significantly lower in-hospital mortality after the approval was observed only among TAVR patients, suggesting that the TAVR use in this young age group expanded towards lower-risk patients. These data suggest the importance of regulatory bodies to

118 delineate the indicated age group for novel indication transcatheter valve devices, as the first 119 guidance specifying the age threshold lagged by 2 years following this FDA approval. 120 Considerations surrounding the patient age is relevant, because low risk is not 121 synonymous to young age in prosthetics with age-dependent durability. Yet, the accelerated 122 increase in TAVR share among young patients around the time of the FDA approval may reflect 123 the public's reception of the low-risk approval. Ongoing trials on moderate or asymptomatic 124 severe aortic stenosis may follow similar trend⁶. Similarly, transcatheter edge-to-edge mitral 125 repair is being compared with surgical mitral valve repair⁷. The trial population will likely be 126 old, with the inclusion criteria of older than 65, which is above the national mean of those undergoing surgical MV repair for degenerative disease⁷. With less competing risks, the long-127 128 term impact of residual mitral regurgitation and the impact of device durability are likely more 129 pronounced in younger patients. As novel devices expand in indications, the momentum of 130 'indication creep'⁵ may be balanced with a clear age threshold for indication by the regulatory 131 bodies. 132 The NIS is claims-based and lacks granular risk characteristics. Therefore, we used in-133 hospital mortality as a surrogate of patient risk profile. Valve pathology diagnosis was missing in 134 15%.

135


136 Conclusion

Expansion of TAVR use among young patients around the time of the FDA approval of
balloon-expandable TAVR in low surgical risk patients serves as a case study to highlight the
potential importance of specifying the indicated age group in future FDA approvals of

- 140 transcatheter valve intervention devices that may have age-dependent durability and unknown
- 141 long-term implications.
- 142
- 143
- 144 References
- 145 1. Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National Trends 146 in TAVR and SAVR for Patients With Severe Isolated Aortic Stenosis. *Journal of the*
- 147 American College of Cardiology. 2022;80(21):2054-2056.
- 148 doi:doi:10.1016/j.jacc.2022.08.787
- 149 2. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement
- 150 with a Balloon-Expandable Valve in Low-Risk Patients. *New England Journal of*
- 151 *Medicine*. 2019;380(18):1695-1705. doi:10.1056/NEJMoa1814052
- 152 3. Hawkins RB, Deeb GM, Sukul D, et al. Redo Surgical Aortic Valve Replacement
- 153 After Prior Transcatheter Versus Surgical Aortic Valve Replacement. JACC:
- 154 *Cardiovascular Interventions*. 2023/04/24/ 2023;16(8):942-953.
- 155 doi:<u>https://doi.org/10.1016/j.jcin.2023.03.015</u>
- 4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the
 Management of Patients With Valvular Heart Disease: A Report of the American College
 of Cardiology/American Heart Association Joint Committee on Clinical Practice
- 158 of Cardiology/American Heart Association Joint Committee on Clinical Practice 159 Guidelines. *Circulation*. 2021;143(5):e72-e227. doi:doi:10.1161/CIR.0000000000000923
- 160 5. Goel SS, Reardon MJ. Indication Creep in Transcatheter Aortic Valve
- 161 Implantation—Data or Desire? *JAMA Cardiology*. 2023;8(6):519-520.
- 162 doi:10.1001/jamacardio.2023.0674
- 163 6. PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance 164 or TAVR (PROGRESS). ClinicalTrials.gov Identifier: NCT04889872. Updated April 29,
- 165 2024. Accessed May 19, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT04889872.
- 166 7. McCarthy PM, Whisenant B, Asgar AW, et al. Percutaneous MitraClip Device or
- 167 Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are
- 168 Candidates for Surgery: Design and Rationale of the REPAIR MR Trial. *Journal of the*
- 169 American Heart Association. 2023;12(4):e027504. doi:doi:10.1161/JAHA.122.027504
- 170

171 Figure 1: Annual Trends of Transcatheter Aortic Valve Replacement Shares and AVR Mortality

172 Among Patients < 65





This figure shows a change in the rate of TAVR share among patients < 65 years of age before
and after the first low-risk indication approval in August 2018 (panel A) and the quarterly inhospital mortality trends among patients < 65 undergoing SAVR and TAVR (panel B). Red lines
are linear regression lines fitted to the TAVR share before and after September 1, 2018. AVR:
Aortic valve replacement; SAVR: Surgical aortic valve replacement; TAVR: Transcatheter aortic
valve replacement.

100

181

182 Supplemental Table: ICD Codes for Procedures and Aortic Pathology Etiologies

183

Procedure or Aortic Pathology	ICD Code
TAVR	02RF37Z, 02RF38Z, 02RF3JZ, 02RF3KZ
Bioprosthetic/biologic SAVR	02RF07Z, 02RF08N, 02RF08Z, 02RF0KZ,
	02RF48N, 02RF48Z, 02RF4KZ, 02RF47Z
Mechanical SAVR	02RF0JZ, 02RF4JZ
Ross Operation ¹	Defined as simultaneous use of biological
	AVR and replacement of pulmonary valve
	with tissue graft, including homograft
Biologic AVR	02RF07Z, 02RF08Z, 02RF0KZ
Replacement of pulmonary Valve with	02RH07Z, 02RH08Z, 02RH0KZ, 02RH47Z
tissue graft, including homograft	
Infective Endocarditis	133, 138, 1339, T826, B376, 139, 1398, 1423,
	I091, I011, A3951, A3282, B3321, A5483
Aortic stenosis	1350
Aortic insufficiency	1351
Mixed aortic stenosis and insufficiency	1352
Congenital AI/AS including BAV	Q2383, Q231, Q230

184

185 AI: Aortic Insufficiency; AS: Aortic Stenosis; BAV: Bicuspid Aortic Valve; SAVR: Surgical

186 Aortic Valve Replacement; TAVR: Transcatheter Aortic Valve Replacement.

187

- 188 1. El-Hamamsy I, Toyoda N, Itagaki S, et al. Propensity-Matched Comparison of the Ross
- 189 Procedure and Prosthetic Aortic Valve Replacement in Adults. *J Am Coll Cardiol*.
- 190 2022;79:805-815.